Zoetis (ZTS) Competitors

AbbVie (NYSE:ABBV) and Zoetis (NYSE:ZTS) are both large-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their analyst recommendations, institutional ownership, earnings, valuation, profitability, risk, media sentiment, dividends and community ranking.

Which has more risk and volatility, ABBV or ZTS?

AbbVie has a beta of 0.58, meaning that its share price is 42% less volatile than the S&P 500. Comparatively, Zoetis has a beta of 0.89, meaning that its share price is 11% less volatile than the S&P 500.

Does the MarketBeat Community favor ABBV or ZTS?

AbbVie received 429 more outperform votes than Zoetis when rated by MarketBeat users. However, 77.94% of users gave Zoetis an outperform vote while only 73.34% of users gave AbbVie an outperform vote.

Company	Underperform	Outperform
AbbVie	Outperform Votes 1337 73.34%	Underperform Votes 486 26.66%
Zoetis	Outperform Votes 908 77.94%	Underperform Votes 257 22.06%

Which has higher earnings & valuation, ABBV or ZTS?

AbbVie has higher revenue and earnings than Zoetis. Zoetis is trading at a lower price-to-earnings ratio than AbbVie, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
AbbVie	$55.53B	5.59	$4.86B	$2.88	60.97
Zoetis	$9.15B	8.13	$2.34B	$5.32	30.98

Do analysts recommend ABBV or ZTS?

AbbVie presently has a consensus price target of $205.70, indicating a potential upside of 17.15%. Zoetis has a consensus price target of $215.22, indicating a potential upside of 30.56%. Given Zoetis' stronger consensus rating and higher possible upside, analysts clearly believe Zoetis is more favorable than AbbVie.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
AbbVie	0 Sell rating(s)	5 Hold rating(s)	17 Buy rating(s)	2 Strong Buy rating(s)	2.88
Zoetis	0 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	2 Strong Buy rating(s)	3.09

Is ABBV or ZTS more profitable?

Zoetis has a net margin of 26.55% compared to AbbVie's net margin of 9.22%. AbbVie's return on equity of 244.01% beat Zoetis' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
AbbVie	9.22%	244.01%	13.44%
Zoetis	26.55%	51.98%	18.41%

Does the media prefer ABBV or ZTS?

In the previous week, AbbVie had 17 more articles in the media than Zoetis. MarketBeat recorded 25 mentions for AbbVie and 8 mentions for Zoetis. Zoetis' average media sentiment score of 0.56 beat AbbVie's score of 0.54 indicating that Zoetis is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
AbbVie	10 Very Positive mention(s)	2 Positive mention(s)	6 Neutral mention(s)	4 Negative mention(s)	0 Very Negative mention(s)	Positive
Zoetis	3 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Positive

Do institutionals and insiders believe in ABBV or ZTS?

70.2% of AbbVie shares are held by institutional investors. Comparatively, 92.8% of Zoetis shares are held by institutional investors. 0.3% of AbbVie shares are held by company insiders. Comparatively, 0.2% of Zoetis shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Is ABBV or ZTS a better dividend stock?

AbbVie pays an annual dividend of $6.56 per share and has a dividend yield of 3.7%. Zoetis pays an annual dividend of $2.00 per share and has a dividend yield of 1.2%. AbbVie pays out 227.8% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. Zoetis pays out 37.6% of its earnings in the form of a dividend. AbbVie has increased its dividend for 53 consecutive years and Zoetis has increased its dividend for 13 consecutive years. AbbVie is clearly the better dividend stock, given its higher yield and longer track record of dividend growth.

Summary

Zoetis beats AbbVie on 11 of the 21 factors compared between the two stocks.